Investor Relations

Latest Event

Global Longevity Federation

Latest Financial Results

FY 2023

Fiscal Year Ended Dec 31, 2023

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2023

Company Overview

At Telomir Pharmaceuticals, we are committed to developing breakthrough science to address the root causes of difficult to treat diseases. By partnering with the brightest minds in science and healthcare, we have the potential to discover and develop ground-breaking treatments to bring about better health for patients and change the future of medicine.

Stock Snapshot

IR Contacts

Headquarters

Telomir Pharmaceuticals, Inc.
855 Wolfe St.
Ste 601.1
Baltimore, MD 21205
United States
T: 813-864-2558
telomir@kcsa.com

Investor Relations

KCSA
Phil Carlson
261 Madison Avenue, 9th Fl.
New York, NY 10016
T: 212-896-1233
telomir@kcsa.com

Transfer Agent

Equiniti
6201 15th Avenue
Brooklyn, NY 11219
T: US 800-401-1957
T: Canada/US Virgin Islands 800-468-9716
T: Other International Access Codes
susan.silber@equiniti.com